ME02054B - Agomelatin hidroklorid hidrat i njegova priprava - Google Patents
Agomelatin hidroklorid hidrat i njegova pripravaInfo
- Publication number
- ME02054B ME02054B MEP-2015-23A MEP2315A ME02054B ME 02054 B ME02054 B ME 02054B ME P2315 A MEP2315 A ME P2315A ME 02054 B ME02054 B ME 02054B
- Authority
- ME
- Montenegro
- Prior art keywords
- hydrochloride hydrate
- agomelatine
- agomelatine hydrochloride
- preparation
- hydrate according
- Prior art date
Links
- ZJVMEXOLMFNQPX-UHFFFAOYSA-N n-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide;hydrochloride Chemical compound Cl.C1=CC=C(CCNC(C)=O)C2=CC(OC)=CC=C21 ZJVMEXOLMFNQPX-UHFFFAOYSA-N 0.000 title claims 14
- 238000002360 preparation method Methods 0.000 title claims 6
- 238000000034 method Methods 0.000 claims 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 6
- 239000003960 organic solvent Substances 0.000 claims 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 3
- YJYPHIXNFHFHND-UHFFFAOYSA-N agomelatine Chemical compound C1=CC=C(CCNC(C)=O)C2=CC(OC)=CC=C21 YJYPHIXNFHFHND-UHFFFAOYSA-N 0.000 claims 3
- 229960002629 agomelatine Drugs 0.000 claims 3
- 239000013078 crystal Substances 0.000 claims 3
- 239000007864 aqueous solution Substances 0.000 claims 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 1
- 206010034912 Phobia Diseases 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- 210000002249 digestive system Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000019899 phobic disease Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000012672 seasonal affective disease Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 230000035882 stress Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Claims (12)
1. Agomelatin hidroklorid hidrat formuleI: naznačen time, da X je Cl.
2. Agomelatin hidroklorid hidrat formule I u skladu s patentnim zahtjevom 1, u kristalnom obliku, naznačen time, da su Braggov kut 2θ, interplanarni razmak D i relativni intenzitet kako slijedi:Relativni intenzitet (I%) a što uključuje i kristale čiji se vrhovi difrakcije nalaze unutar pogreške od +/- 0,2°.
3. Postupak za pripremu agomelatin hidroklorid hidrata u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da agomelatin reagira s HCl u vodenom organskom otapalu, čime se dobiva agomelatin hidroklorid hidrat.
4. Postupak za pripremu agomelatina hidroklorid hidrata u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da se agomelatin otopi u organskom otapalu prije dodavanja vodene otopine HCl da se istaloži kristal proizvoda.
5. Postupak za pripremu agomelatina hidroklorid hidrata u skladu s patentnim zahtjevom 4, naznačen time, da se vodena otopina HCl dodaje kap po kap.
6. Postupak za pripremu agomelatina hidroklorid hidrata u skladu s patentnim zahtjevom 3, naznačen time, da se agomelatin dodaje vodenom organskom otapalu koje sadrži HCl da se istaloži kristal proizvoda.
7. Postupak za dobivanje agomelatin hidroklorid hidrata u skladu sa zahtjevom 4 ili 6, naznačen time, da nadalje uključuje ispiranje i sušenje krutine nakon kristalizacije.
8. Postupak za dobivanje agomelatin hidroklorid hidrata u skladu sa zahtjevom 4 ili 6, naznačen time, da je temperatura reakcije 0-20 ° C.
9. Postupak za dobivanje agomelatina hidroklorid hidrata u skladu s patentnim zahtjevom 4 ili 6, naznačen time, da je organsko otapalo etil-acetat, metil-acetat, n-butil acetat, aceton ili acetonitril.
10. Postupak za pripremu agomelatina hidroklorid hidrata prema zahtjevu 9, naznačen time, da je organsko otapalo etil acetat.
11. Farmaceutska tableta, koja sadrži agomelatin hidroklorid hidrat u skladu s patentnim zahtjevom 1 ili 2, naznačena time, da je tableta u kombinaciji s farmaceutski prihvatljivim pomoćnim tvarima ili ekscipijensima.
12. Uporaba agomelatina hidroklorid hidrata prema zahtjevu 1 ili 2, naznačena time, da je namijenjena za liječenje poremećaja melatonergičkog sustava, poremećaja spavanja, stresa, anksioznosti, sezonskih depresija, velike depresije, kardiovaskularnih bolesti, bolesti probavnog sustava, nesanice i umora uslijed promjene vremenske zone (jet lag), shizofrenije, fobije ili depresivnih poremećaja.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010126254XA CN102190594A (zh) | 2010-03-17 | 2010-03-17 | 阿戈美拉汀氯化氢水合物及其制备方法 |
| EP11755679.5A EP2547649B1 (en) | 2010-03-17 | 2011-03-17 | Agomelatine hydrochloride hydrate and preparation thereof |
| PCT/CN2011/071910 WO2011113362A1 (en) | 2010-03-17 | 2011-03-17 | Agomelatine hydrochloride hydrate and preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02054B true ME02054B (me) | 2015-05-20 |
Family
ID=44599556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2015-23A ME02054B (me) | 2010-03-17 | 2011-03-17 | Agomelatin hidroklorid hidrat i njegova priprava |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US8729131B2 (me) |
| EP (1) | EP2547649B1 (me) |
| JP (1) | JP5634532B2 (me) |
| KR (1) | KR101406727B1 (me) |
| CN (2) | CN102190594A (me) |
| AP (1) | AP2012006492A0 (me) |
| AU (1) | AU2011229618B2 (me) |
| BR (1) | BR112012023317B1 (me) |
| CA (1) | CA2792417C (me) |
| CL (1) | CL2012002540A1 (me) |
| CR (1) | CR20120462A (me) |
| CU (1) | CU20120137A7 (me) |
| CY (1) | CY1116086T1 (me) |
| DK (1) | DK2547649T3 (me) |
| EA (1) | EA022067B1 (me) |
| EC (1) | ECSP12012155A (me) |
| ES (1) | ES2530772T3 (me) |
| GE (1) | GEP20156231B (me) |
| GT (1) | GT201200259A (me) |
| HR (1) | HRP20150071T1 (me) |
| IL (1) | IL221782A (me) |
| MA (1) | MA34055B1 (me) |
| ME (1) | ME02054B (me) |
| MX (1) | MX2012010541A (me) |
| NI (1) | NI201200140A (me) |
| NZ (1) | NZ602450A (me) |
| PE (1) | PE20130013A1 (me) |
| PH (1) | PH12012501757A1 (me) |
| PL (1) | PL2547649T3 (me) |
| PT (1) | PT2547649E (me) |
| RS (1) | RS53815B1 (me) |
| SG (1) | SG183868A1 (me) |
| SI (1) | SI2547649T1 (me) |
| TN (1) | TN2012000435A1 (me) |
| UA (1) | UA105425C2 (me) |
| WO (1) | WO2011113362A1 (me) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2551257A1 (en) * | 2011-07-28 | 2013-01-30 | Laboratorios Del. Dr. Esteve, S.A. | Co-crystals of agomelatine with co-crystal-formers |
| FR2978916B1 (fr) | 2011-08-10 | 2013-07-26 | Servier Lab | Composition pharmaceutique solide pour administration buccale d'agomelatine |
| EP2851363B1 (en) * | 2012-05-14 | 2018-01-03 | Shanghai Righthand Pharmtech. Co., Ltd. | Agomelatine acid radical composite, and preparation method and application thereof |
| CN102702041B (zh) * | 2012-05-14 | 2013-08-14 | 上海右手医药科技开发有限公司 | 阿戈美拉汀苯磺酸类复合物及其制备方法 |
| CN102718675B (zh) * | 2012-06-07 | 2015-03-25 | 上海右手医药科技开发有限公司 | 阿戈美拉汀甲磺酸复合物及其制备方法 |
| CN102718676B (zh) * | 2012-06-26 | 2014-04-09 | 福建广生堂药业股份有限公司 | 阿戈美拉汀硫酸盐及其制备方法 |
| EP2934502A1 (en) | 2012-12-21 | 2015-10-28 | Laboratorios Lesvi S.L. | Process for prepararing n-(2-(7-methoxy-1-naphthalenyl)ethyl) acetamide and solid forms thereof |
| FR3001894A1 (fr) | 2013-02-08 | 2014-08-15 | Servier Lab | Composition pharmaceutique solide pour administration buccale d'agomelatine |
| WO2015013865A1 (en) * | 2013-07-29 | 2015-02-05 | Les Laboratoires Servier | Agomelatine sulfonic acids complexes and preparation thereof |
| KR101470794B1 (ko) | 2014-06-30 | 2014-12-08 | 순천향대학교 산학협력단 | 아고멜라틴 공결정의 제조 방법 및 이를 포함하는 조성물 |
| HRP20211511T1 (hr) * | 2015-07-02 | 2021-12-24 | Acerta Pharma B.V. | Čvrsti oblici i formulacije (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benzamida |
| US10397136B2 (en) * | 2016-08-27 | 2019-08-27 | Nicira, Inc. | Managed forwarding element executing in separate namespace of public cloud data compute node than workload application |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2658818B1 (fr) * | 1990-02-27 | 1993-12-31 | Adir Cie | Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| HRP20030432A2 (en) * | 2000-10-30 | 2004-06-30 | Teva Pharma | Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation |
| FR2890562B1 (fr) * | 2005-09-09 | 2012-10-12 | Servier Lab | Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles du sommeil chez le patient deprime |
| FR2899472B1 (fr) * | 2006-04-07 | 2008-09-12 | Servier Lab | Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble anxiete generalisee |
| FR2934859B1 (fr) * | 2008-08-05 | 2010-08-13 | Servier Lab | Nouveau procede de synthese de l'agomelatine |
| CN101481321B (zh) * | 2009-02-27 | 2012-04-18 | 上海医药工业研究院 | 阿戈美拉汀卤化氢复合物及其制备方法 |
| WO2012046253A2 (en) * | 2010-10-08 | 2012-04-12 | Msn Laboratories Limited | Process for the preparation of n-[2- (7-methoxy-l-naphthyl) ethyl] acetamide and its novel crystalline forms |
-
2010
- 2010-03-17 CN CN201010126254XA patent/CN102190594A/zh active Pending
-
2011
- 2011-03-17 DK DK11755679.5T patent/DK2547649T3/en active
- 2011-03-17 PT PT117556795T patent/PT2547649E/pt unknown
- 2011-03-17 NZ NZ602450A patent/NZ602450A/en not_active IP Right Cessation
- 2011-03-17 MA MA35192A patent/MA34055B1/fr unknown
- 2011-03-17 CA CA2792417A patent/CA2792417C/en active Active
- 2011-03-17 PL PL11755679T patent/PL2547649T3/pl unknown
- 2011-03-17 SG SG2012065009A patent/SG183868A1/en unknown
- 2011-03-17 HR HRP20150071AT patent/HRP20150071T1/hr unknown
- 2011-03-17 ES ES11755679T patent/ES2530772T3/es active Active
- 2011-03-17 JP JP2012557392A patent/JP5634532B2/ja not_active Expired - Fee Related
- 2011-03-17 KR KR1020127026895A patent/KR101406727B1/ko not_active Expired - Fee Related
- 2011-03-17 AP AP2012006492A patent/AP2012006492A0/xx unknown
- 2011-03-17 ME MEP-2015-23A patent/ME02054B/me unknown
- 2011-03-17 US US13/635,063 patent/US8729131B2/en active Active
- 2011-03-17 PH PH1/2012/501757A patent/PH12012501757A1/en unknown
- 2011-03-17 EP EP11755679.5A patent/EP2547649B1/en active Active
- 2011-03-17 BR BR112012023317-3A patent/BR112012023317B1/pt not_active IP Right Cessation
- 2011-03-17 SI SI201130403T patent/SI2547649T1/sl unknown
- 2011-03-17 CN CN201180024357.8A patent/CN102958911B/zh not_active Expired - Fee Related
- 2011-03-17 UA UAA201211720A patent/UA105425C2/ru unknown
- 2011-03-17 MX MX2012010541A patent/MX2012010541A/es active IP Right Grant
- 2011-03-17 EA EA201201294A patent/EA022067B1/ru unknown
- 2011-03-17 WO PCT/CN2011/071910 patent/WO2011113362A1/en not_active Ceased
- 2011-03-17 RS RS20150041A patent/RS53815B1/sr unknown
- 2011-03-17 AU AU2011229618A patent/AU2011229618B2/en not_active Ceased
- 2011-03-17 PE PE2012001448A patent/PE20130013A1/es active IP Right Grant
- 2011-03-17 GE GEAP201112869A patent/GEP20156231B/en unknown
-
2012
- 2012-08-31 TN TNP2012000435A patent/TN2012000435A1/en unknown
- 2012-09-04 IL IL221782A patent/IL221782A/en not_active IP Right Cessation
- 2012-09-11 CR CR20120462A patent/CR20120462A/es unknown
- 2012-09-12 NI NI201200140A patent/NI201200140A/es unknown
- 2012-09-13 CL CL2012002540A patent/CL2012002540A1/es unknown
- 2012-09-14 EC ECSP12012155 patent/ECSP12012155A/es unknown
- 2012-09-17 GT GT201200259A patent/GT201200259A/es unknown
- 2012-09-17 CU CU2012000137A patent/CU20120137A7/es unknown
-
2015
- 2015-01-22 CY CY20151100071T patent/CY1116086T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02054B (me) | Agomelatin hidroklorid hidrat i njegova priprava | |
| CN104230777B (zh) | 一种奥拉西坦的合成方法 | |
| HRP20191525T1 (hr) | Inhibitori replikacije virusa influence | |
| ME02309B (me) | Agomelatin hidrobromid hidrat i njegova priprema | |
| HRP20201275T1 (hr) | Kristalni oblik derivata benzimidazola i postupak njegove proizvodnje | |
| MEP34408A (en) | New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal | |
| RU2013158816A (ru) | Новые сокристаллы агомелатина, способ их получения и фармацевтические композиции, которые их содержат | |
| HRP20150327T1 (hr) | Kristalni oblici klorovodiäśne soli (4a-r,9a-s)-1-(1h-benzoimidazol-5-karbonil)-2,3,4,4a,9,9a-heksahidro-1h-indeno [2,1-b]piridin-6-karbonitrila i njihova uporaba kao hsd 1 inhibitora | |
| RS56846B1 (sr) | Jedinjenja korisna za sintezu jedinjenja benzamida | |
| ME02731B (me) | Mješoviti kristalni oblik agomelatina. (oblik-viii), postupak pripreme i njegove primjene i farmaceutski pripravak koji ga sadrži | |
| CN104292231A (zh) | 一种枸橼酸托法替尼的制备方法 | |
| CN103524400B (zh) | 一种n-(2’,6’-二甲苯基)-2-哌啶甲酰胺类局麻药的纯化方法 | |
| HRP20171831T1 (hr) | Novi kristalni oblik vii agomelatina, postupak pripreme i njegova uporaba i farmaceutski pripravak koji sadržava novi kristalni oblik vii agomelatina | |
| CN107090000B (zh) | 一种苯并硼唑7位脂肪酸的衍生物及其制备与用途 | |
| WO2015113321A1 (zh) | 二氨基胍衍生物及其在制备动物饲用生长促进剂中的应用 | |
| CN109721579A (zh) | 7,8-脱氢葡萄藤戊素衍生物、其制法和药物组合物与用途 | |
| AU2009269720A1 (en) | Chromane derivatives as TRPV3 modulators | |
| ES2655431T3 (es) | Método para la preparación de derivados de tiazol | |
| CN111518111B (zh) | 脱氧柠檬苦素a环开环胺化衍生物或其药学上可接受的盐、制备方法及用途 | |
| CN108484611B (zh) | 一种简单合成蕨藻红素的方法 | |
| ES2246916T3 (es) | Derivados de bencimidazol sustituidos con carboxamida, procedimiento para su preparacion y su empleo como inhibidores de triptasa. | |
| CN115677610B (zh) | 苯并噁唑啉酮衍生物及其制备方法和用途 | |
| CN103113243A (zh) | 一种2-（7-甲氧基-1-萘基）乙胺盐酸盐的合成方法 | |
| CN104844577A (zh) | 埃索美拉唑镁的晶型 | |
| CN111808172B (zh) | 肺念菌素b0衍生物及其制备方法和用途 |